Evidence map›Paper›PMID 34592239›Full record

ArticleHuman pathology2022

Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.

Michael Torbenson, Chantal E McCabe, Daniel R O'Brien, Jun Yin, Tiffany Bainter, Nguyen H Tran, Saba Yasir, Zongming Eric Chen, Renu Dhanasekaran, Keun Soo Ahn and 2 more

Open access · greenAbstract read
In one paragraph

Article in Human pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Michael TorbensonMayo Clinic Department of Pathology and Laboratory Medicine, United States. Electronic address: Torbenson.Michael@mayo.edu.
Chantal E McCabeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
Daniel R O'BrienDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
Jun YinDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States.
Tiffany BainterDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States.
Nguyen H TranDepartment of Oncology, Mayo Clinic, Rochester, MN, United States.
Saba YasirMayo Clinic Department of Pathology and Laboratory Medicine, United States.
Zongming Eric ChenMayo Clinic Department of Pathology and Laboratory Medicine, United States.
Renu DhanasekaranDivision of Gastroenterology and Hepatology, Stanford University, Stanford, CA, United States.
Keun Soo AhnDepartment of Surgery, Keimyung University School of Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Kore.
Lewis R RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States.
Chen WangDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
Mayo Clinic in Florida · USWinnMed · USMayo Clinic · USMayo Clinic in Arizona · USKeimyung University · KRStanford University · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Rory Smoot · 2018 to 2026
$20.5M
Functional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC)K08CA222676 · NCI · STANFORD UNIVERSITY · PI DHANASEKARAN, RENUMATHY · 2018 to 2022
$1.0M
NCI NIH HHS K08 CA222676NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA210964
6 · The paper itself

Abstract

Beta-catenin (CTNNB1) is commonly mutated in hepatocellular carcinoma (HCC). CTNNB1-mutated HCC has important clinical correlates, such as being immune cold and less likely to respond to immune checkpoint inhibitor therapies. It remains unclear, however, if they are a morphologically homogenous group of tumors. To better understand the association between the morphology, CTNNB1 mutations, and other molecular features, a detailed study of 338 The Cancer Genome Atlas cases was performed. A characteristic histological morphology was strongly associated with CTNNB1 mutations but was present in only 58% of CTNNB1-mutated HCCs. Tumors with APC mutations tended to have the classic morphology; those with AXIN mutations did not. Pseudoglands are a key feature of the classic morphology, and they were associated with CTNNB1 mutations, male gender, specific CTNNB1 mutation site, and lack of TP53 mutations. Differential gene expression analysis stratified by the presence/absence of pseudoglands identified 60 differentially expressed genes (FDR <5%); clustering according to these differentially expressed genes revealed three groups of tumors, one with pseudoglands and a strong association with genes regulated by Wnt signaling; within this group, TP53 mutations were associated with a loss of the typical morphology of CTNNB1-mutated HCCs. When stratified by gender, further differential gene expression showed Wnt-regulated genes were associated with pseudoglands in men but not women. These findings indicate HCC with CTNNB1 mutations are morphologically heterogeneous, with gene penetrance for morphology dependent in part on gender, specific CTNNB1 mutations, and co-occurring TP53 mutations. This heterogeneity has important implications for the classification of HCC.

Indexed as

MutationAdultAgedbeta CateninBiomarkers, TumorCarcinoma, HepatocellularFemaleGenetic Predisposition to DiseaseHumansLiver NeoplasmsMaleMiddle AgedNeoplasm GradingPhenotypeTumor Suppressor Protein p53Wnt Proteinsbeta CateninBiomarkers, TumorCTNNB1 protein, humanTP53 protein, humanTumor Suppressor Protein p53Wnt ProteinsAPCAXINCTNNB1Differential gene expressionSurvival

Identifiers

PMID34592239
PMCPMC9258524
OpenAlexW3202842501

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.